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Higher plasma betatrophin/
ANGPTL8 level in Type 2 Diabetes 
subjects does not correlate with 
blood glucose or insulin resistance
Mohamed Abu-Farha1, Jehad Abubaker1, Irina Al-Khairi1, Preethi Cherian1, Fiona Noronha2, 
Frank B. Hu3, Kazem Behbehani1,2 & Naser Elkum4
Betatrophin/ANGPTL8 is a newly identified hormone produced in liver and adipose tissue that has 
been shown to be induced as a result of insulin resistance and regulates lipid metabolism. Little is 
known about betatrophin level in humans and its association with T2D and metabolic risk factors. 
Plasma level of betatrophin was measured by ELISA in 1603 subjects: 1047 non-diabetic and 556 
T2D subjects and its associations with metabolic risk factors in both non-diabetic and T2D were 
also studied. Our data show a significant difference in betatrophin levels between non-diabetic 
(731.3 (59.5–10625.0) pg/ml) and T2D (1710.5 (197.4–12361.1) p < 0.001. Betatrophin was positively 
correlated with age, BMI, waist/hip ratio, FBG, HbA1C, HOMA-IR and TG in the non-diabetic subjects. 
However, no association was observed with BMI, FBG, HbA1C or HOMA-IR in T2D subjects. TC and 
LDL showed negative association with betatrophin in T2D subjects. Multivariate analysis showed that 
subjects in the highest tertile of betatrophin had higher odds of having T2D (odd ratio [OR] = 6.15, 
95% confidence interval [CI] = (3.15 – 12.01). Our data show strong positive associations between 
betatrophin and FBG and insulin resistance in non-diabetic subjects. However, correlations with FBG 
and insulin resistance were diminished in T2D subjects.
Type 2 Diabetes (T2D) is a major burden to human health, affecting over 336 million people worldwide1. 
While autoimmune system destruction of β -cells is the main cause of β -cell loss in type 1 diabetes 
(T1D)2–4, the failure of β -cells to compensate for ambient insulin resistance leads to uncontrolled hyper-
glycemia in T2D1,5–8. Even though glycemic control can be achieved through the use of various types 
of anti-diabetic drugs including insulin injection, full glycemic control similar to functional β -cells is 
hard to achieve9. Alternatively, enhancing the proliferation of β -cells in the pancreas can lead to better 
treatments for T2D10. Existing inducers of insulin secretion or β -cell replication such as glucagon-like 
peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are not specific to this type of cells and 
only cause a small increase in β -cell proliferation7. A novel protein called betatrophin has been recently 
found to increase the beta-cell mass in an insulin resistance mouse model9. To do so, Yi et al., generated 
an insulin resistant mouse model using an insulin receptor antagonist and showed that betatrophin was 
up-regulated in the liver and fat tissues. It’s over expression was shown to cause a 17-fold increase in 
β -cell proliferation and to increase β -cell mass in mice9.
Betatrophin is yet another name given to C19orf80, which is also called Hepatocellular 
Carcinoma-Associated Gene TD26. Ren et al., gave betatrophin the name RIFL (refeeding induced in fat 
and liver) as they demonstrated that betatrophin was induced in 3T3 L1 cells during adipogenesis and its 
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knockdown led to a reduction in adipogenesis11. Betatrophin was also given the name angiopoietin-like 
8 (ANGPTL8) as it shares significant sequence similarity with the ANGPTL protein family particularly 
ANGPTL3. Betatrophin and ANGPTL3 were shown to interact at the protein level affecting levels of 
triglycerides (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol 
(LDL-C)12. In addition, Quagliarini et al., showed that a non-synonymous variant in betatrophin that 
changes amino acid 59 from Arginine (R) to Tryptophan (W) (R59W) was associated with lower HDL-C 
and LDL-C levels in human plasma12. Due to its activity in lipoprotein lipase inhibition, betatrophin was 
also called Lipasin; its expression was induced by cold shock at 4 °C and a high fat diet, while fasting 
reduced its expression13,14.
Liver produced hormones have been suggested as potential mediators of the increased β -cell prolif-
eration under an insulin resistant state15,16. Betatrophin has been suggested as another example of a liver 
derived hormone that is capable of inducing β -cell proliferation by Yi et al9. They have suggested that 
betatrophin levels are regulated by insulin resistance and not insulin deficiency in mice, suggesting a 
strong role for this protein in T2D9. However, this work has been disputed in a recent article by Gusarova 
et al. which showed that mice lacking betatrophin/ANGPTL8 had a normal β -cell expansion under states 
of insulin resistance induced by high-fat diet or treatment with insulin receptor antagonist S96117. In 
response, Yi et al. repeated their experiments and failed to replicate their earlier experiment concluding 
that betatrophin does not regulate β -cell expansion18. Recent reports have shown that betatrophin was 
increased in T2D19,20 while others suggested that betatrophin was reduced in subjects with T2D21. To 
address this question, this study evaluated the association of betatrophin with blood sugar and IR in 
subjects with-and-without T2D in a large sample set.
Research Design and Methods
Study Participants. In order to understand the role of betatrophin in T2D, plasma samples from 
1603 adult (> 18 years old) South Asians and Arabs living in Kuwait were used. This is part of a large 
cohort that has been randomly collected from multi-ethnic subjects living in Kuwait as described pre-
viously22–24. Briefly, a stratified random sampling technique was used for the selection of participants 
from the computerized register of the Public Authority of Civil Information. This survey was carried out 
between June 2011 and August 2012. A total of 3468 subjects randomly selected across the six governo-
rates (strata) of Kuwait were collected. 722 subjects were diabetics. A total of 556 T2D subjects were used 
in this study after excluding subjects with T1D and cardiovascular diseases. Study participants suffering 
from any kind of infection as well as subjects younger than 18 and older than 65 were excluded. Controls 
were then selected as subjects without disease and not taking any medications, as a result, a total of 1047 
non-diabetic subjects were selected. The selected non-diabetic subjects had similar population charac-
teristics as the total study population in terms of age, gender, FBG, BMI, BP and lipid profile. The study 
conformed to the principles outlined in the Declaration of Helsinki and in accordance with the approved 
guidelines. The study was approved by the Scientific Advisory Board and Ethical Review Committee at 
Dasman Diabetes Institute (DDI). An informed written consent was obtained from all the participants 
before their enrolment in the study.
Anthropometric and Physical Measurements. Physical and anthropometric measurements taken 
were: body weight, height, waist circumference (WC) and BP. BP was measured using an Omron HEM-
907XL Digital sphygmomanometer. An average of 3 BP readings, with 5 to 10 minutes rest between each, 
was obtained. Height and weight were measured, with participants wearing light indoor clothing and 
barefooted, using calibrated portable electronic weighing scales and portable inflexible height measuring 
bars. WC was measured using constant tension tape at the end of a normal exhalation, with arms relaxed 
at the sides, at the highest point of the iliac crest and at the mid-axillary line. BMI was calculated using 
the standard BMI formula: body weight (in kilograms) divided by height (in meters squared).
Laboratory Measurements. Blood samples were obtained after fasting overnight for at least 10 hours 
and analyzed for FBG, HbA1c, fasting insulin, and lipid profiles that included TG, TC, LDL and HDL. 
Glucose and lipid profiles were measured on the Siemens Dimension RXL chemistry analyzer (Diamond 
Diagnostics, Holliston, MA). HbA1c was determined using the VariantTM device (BioRad, Hercules, 
CA). All laboratory tests were performed by certified technicians at the clinical laboratories of DDI using 
the Ministry of Health approved methods and quality standards. Insulin was measured using the Access 
Ultrasensitive Insulin Assay (Beckman Coulter, Brea, CA). Intra- and intra- assay coefficients of variation 
were ≤ 6%. Insulin resistance was calculated using HOMA-IR formula: FBG (mmol/L) x fasting insulin 
(mU/L) / 22.5. HOMA-β was calculated using the following formula (20 x fasting insulin (mU/L) / FBG 
(mmol/L)-3.5)*100%.
Diabetes diagnosis and guidelines. The current recommendations and updated guidelines for 
the definition, diagnosis and classification of T2D, published by the International Diabetes Federation 
(IDF), have been used 25. Diabetes was defined by fasting plasma glucose ≥ 7 mmol/l, under treatment, 
or self-reporting of previously diagnosed T2D25. Impaired fasting glucose (IFG) was defined by fasting 
blood glucose values ≥ 5.6 and < 7 mmol/L.
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ELISA Betatrophin and Level. Blood samples were drawn into vacutainer EDTA aprotinin tubes. 
Plasma was obtained after centrifugation for 10 minutes at 2000 g at room temperature. Plasma was then 
aliquoted into cryogenic tubes and stored at − 80 °C. Plasma samples stored at − 80 °C freezers were 
thawed on ice and centrifuged at 10000 g for 5 minutes at °C 4 to remove any debris. Samples used to 
measure level of betatrophin were not exposed to freeze thaw cycles. Betatrophin concentration was 
determined using ELISA (Wuhan EIAAB Science co) as described previously26,27. Current ELISA kit 
was validated against other available kits showing correlation coefficient of 0.9928. Furthermore, we have 
validated the current kit using recombinant betatrophin. A range of betatrophin concentrations were 
used to spike in plasma at different dilution factors. The assay showed linearity at dilutions ranging from 
1:10–1:40. Recovery of the known proteins ranged from 85–109%. No significant cross reactivity with 
other proteins was observed. Intra-assay coefficients of variation were 1.2% to 3.8%, while the inter-assay 
coefficients of variation were 6.8% to 10.2%.
Statistical Analysis. Normality tests were used to assess data distribution. Comparisons between 
subjects with T2D and without T2D were made by Student’s t-test or Wilcoxon test for non-parametric 
analyses in variables with non-normal distribution. To assess the difference in categorical variables 
between subjects with and without T2D, a Chi-Squared test was used. Spearman’s correlation coefficients 
were estimated to determine associations between betatrophin and anthropometric measurements and 
biochemical variables. Subjects were classified into tertiles based on their circulating betatrophin levels 
in the overall population. Tertile values of betatrophin are expressed as T1 (< 700 pg/mL), T2 (700 – 
1287.5 pg/mL), and T3 (> 1287.5 pg/mL). A multivariable logistic regression analysis was performed to 
estimate odds ratios (ORs) adjusted for covariates and to assess the predictive effect of betatrophin on 
risk for T2D. All data are reported as Mean ± Standard Deviation (SD) and range, unless stated other-
wise. Research Electronic Data Capture (REDCap) was used for data collections and data management. 
All statistical assessments were two-sided and considered to be significant when P-value < 0.05. All anal-
yses were performed using SAS (ver sion 9.2; SAS Institute, Cary, NC).
Results
Characteristics of the study population are outlined in Table 1. Our population was made of 1603 sub-
jects, 1047 of which were non-diabetic and 556 were T2D. The average age of participants was 42.5 ± 10.3 
for non-diabetic subjects and 53.2 ± 9.7 for subjects with T2D. Subjects with T2D had a significantly 
higher BMI, waist/hip ratio, systolic BP, diastolic BP, FBG, HBA1C, insulin, HOMA-IR, TG, TC, HDL, 
and LDL (p < .05). Betatrophin showed more than a two fold increase in subjects with T2D (1710.5 
(197.4 – 12361.1) pg/mL) relative to non-diabetic subjects (731.3 (59.5 – 10625.0) pg/mL).
Using Spearman’s correlation adjusted for gender and ethnicity betatrophin was positively associated 
with age (r = 0.49, p = < 0.0001), BMI (r = 0.14, p = < 0.0001), waist/hip ratio (r = 0.16, p = < 0.0001), 
FBG (r = 0.19, p = < 0.0001), HbA1c (r = 0.14, p = < 0.0001) insulin (r = 0.14, p = < 0.0001), HOMA-IR 
(r = 0.17, p = < 0.0001) and TG (r = 0.15, p = < 0.0001) in the non-diabetic subjects (Table 2). In the T2D 
subjects betatrophin only showed significant correlation with age (r = 0.46, p = < 0.0001), waist/hip ratio 
(r = 0.18, p = < 0.0001) and duration of T2D (r = 0.29, p = < 0.0001). It also showed negative correlation 
with TC (r = − 0.25, p = < 0.0001) and LDL(r = − 0.27, p = < 0.0001). No correlation was observed with 
BMI, FBG, HbA1C and HOMA-IR or HOMA-β (Table 2).
As shown by Spearman’s correlation (Table 2), betatrophin levels were associated with increased dura-
tion of T2D. Stratifying T2D patients according to duration of the disease showed that people with a 
longer duration of diabetes had higher betatrophin levels. Subjects with T2D for less than 5 years had 
the least square means of betatrophin, 1315.5 (38.1–74.5) pg/mL, compared to 1898.3 (176.7–346.3) pg/
mL for subjects that had T2D for 5–10 years and 2569.6 (139.0–272.3) pg/mL for subjects who had T2D 
for longer than 10 years (Fig. 1).
After adjusting for age, gender and ethnicity (model 1), subjects in the highest tertile of betatrophin 
were more likely to have T2D (OR = 10.94, 95% CI = 7.29 – 16.42) (Table  3). After additional adjust-
ment for BMI and waist/hip ratio, the results did not materially change. Compared to subjects in the 
lowest tertile of betatrophin, those in the highest tertile had higher odds of having T2D (OR = 10.09, 
95% CI = 6.68 – 15.24). Further adjustment for HbA1c, HOMA-IR and HOMA-β moderately attenuated 
the association, but subjects in the highest tertile still had higher odds of having T2D (OR = 7.37, 95% 
CI = 3.87 – 14.04) (p-trend < 0.0001) (Table 3). Adjusting for total cholesterol, triglyceride, LDL, HDL, 
systolic, diastolic blood pressure + Model 3 further attenuated the association showing that subjects in 
the highest tertiles of betatrophin had higher odds of having T2D (OR = 6.15, 95% CI = 3.15 – 12.01) 
(p-trend < 0.0001).
Multivariate regression analysis showed that FBG and HOMA-IR were significantly associated with 
higher betatrophin levels (Fig. 2). Age-, gender- and ethnicity-adjusted least square means of concentra-
tions of betatrophin, according to FBG and HOMA-IR are shown in Fig. 2. Data presented in Fig. 2A 
shows the association between increased insulin resistance and increasing levels of betatrophin (p-trend 
< 0.0001). Figure 2B shows that increased betatrophin levels were significantly associated with increased 
FBG levels (p-trend < 0.0001).
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Variables
Non-diabetic 
(n = 1047) T2D (n = 556) P-value
Age (years) 42.5 ± 10.3 53.2 ± 9.7 < 0.0001
Gender
Male 597(57.02%) 348(62.59%) 0.0310
Female 450(42.98%) 208(37.41%)
Ethnicity
Arab 596(56.92%) 371(66.73%) 0.0001
South Asian 451(43.08%) 185(33.27%)
BMI (kg/m2) 29.31 ± 6.02 31.35 ± 5.84 < 0.0001
Waist/hip ratio 0.91 ± 0.09 0.95 ± 0.06 < 0.0001
Systolic (mmHg) 128.59 ± 18.42 138.43 ± 19.71 < 0.0001
Diastolic (mmHg) 78.96 ± 12.03 80.98 ± 11.34 0.0008
FBG (mmol/L) 5.09 ± 0.57 8.97 ± 3.32 < 0.0001
HBA1C (DCCT%) 5.51 ± 0.61 8.09 ± 1.97 < 0.0001
Insulin (mU/L) 9.00 ± 5.55 14.35 ± 12.03 < 0.0001
HOMAIR 2.08 ± 1.41 5.75 ± 5.34 < 0.0001
Total cholesterol (mmol/L) 5.18 ± 1.06 4.95 ± 1.13 < 0.0001
Triglycerides (mmol/L) 1.42 ± 0.81 1.88 ± 1.37 < 0.0001
HDL cholesterol (mmol/L) 1.16 ± 0.33 1.08 ± 0.28 < 0.0001
LDL cholesterol (mmol/L) 3.04 ± 0.95 3.40 ± 0.95 < 0.0001
Subjects taking insulin 
injection 174 (31.29%
Creatinine μ mol/L 77.50 ± 18.18 81.92 ± 29.68 0.0014
Betatrophin (pg/mL) 731.3 (59.5 – 10625.0) 1710.5 (197.4 – 12361.1) < 0.0001
Table 1.  Clinical and biochemical profiles for non-diabetic and T2D subjects. Results are reported as Mean 
± SD except for non-normally distributed betatrophin that are presented as Median (interquartile range). 
Diabetes: fasting blood glucose ≥ 7 mmol/l, under treatment, or self-reported of previously diagnosed T2D; 
WC, waist circumference.
Variables
Non-diabetic T2D
ρ P-value ρ P-value
Age (years) 0.49 < 0.0001 0.46 < 0.0001
BMI (kg/m2) 0.14 < 0.0001 − 0.04 0.3931
Waist/hip ratio 0.16 < 0.0001 0.18 < 0.0001
FBG (mmol/L) 0.19 < 0.0001 − 0.04 0.3162
HbA1C, % 0.14 < 0.0001 0.02 0.6140
Insulin (mU/L) 0.14 < 0.0001 − 0.02 0.6680
HOMA-IR 0.17 < 0.0001 − 0.03 0.4776
HOMA-β 0.05 0.1526 0.01 0.7070
Total cholesterol (mmol/L) 0.05 0.0845 − 0.25 < 0.0001
Triglycerides (mmol/L) 0.15 < 0.0001 − 0.02 0.5714
HDL cholesterol (mmol/L) − 0.03 0.3995 0.001 0.9819
LDL cholesterol (mmol/L) 0.02 0.5426 − 0.27 < 0.0001
Diabetes duration (years) - - 0.29 < 0.0001
Table 2.  Spearman correlations between betatrophin levels and T2D risk factors. BMI, FBG, T2D: fasting 
blood glucose ≥ 7 mmol/l, under treatment, or self-reported of previously diagnosed T2D. Duration of T2D 
was calculated for subjects with diabetes. Partial Spearman correlation coefficients were adjusted for age, 
gender, and ethnicity.
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Discussion
In this study, we have used a large sample size to look at the level of betatrophin in 1047 non-diabetic 
and 556 T2D subjects. Our data clearly demonstrated an increase in betatrophin level in T2D compared 
to non-diabetic. Betatrophin level showed strong correlation with age in older subjects in both T2D and 
non-diabetic subjects. However, correlations with BMI, FBG, TG and HOMA-IR were only observed in 
non-diabetic subjects. In T2D subjects, betatrophin showed significant positive correlation with waist/
hip ratio and negative correlation with LDL and TC. Betatrophin levels showed significant increase in 
subjects with longer duration of T2D. Finally, higher betatrophin levels were associated with more than 
six-fold increase in the odds of having T2D after adjustment for a wide range of risk factors.
Recent reports investigating betatrophin link to T2D circulation showed contradictory data. A num-
ber of studies showed that betatrophin level was increased in T2D subjects19–21 while, Gomez-Ambrosi et 
al. showed that betatrophin was reduced in T2D subjects29. In the current study, we showed that circu-
lating levels of betatrophin were increased in subjects with T2D compared to subjects without T2D. This 
increase may be related to increased insulin resistance and higher demand for insulin in T2D subjects. 
Our data agrees with data reported in mice showing that betatrophin levels were up-regulated by 3–4 
folds at the transcription level in the liver of the db/db and ob/ob mice models compared to wild-type9. 
This trend in increased betatrophin levels were also observed in patients with longer duration of T2D in 
our population as shown in Fig. 1. More recent reports have also showed that betatrophin was increased 
Figure 1. Age-, gender- and ethnicity-adjusted least square mean estimate of betatrophin in T2D 
patients plotted against duration of T2D .
T1, n = 537 T2D n = 45 
Non-diabetic n = 492
T2, n = 532 T2D n = 149 
Non-diabetic n = 383
T3, n = 534 T2D n = 362 Non-
diabetic n = 140 P-trend
Betatrophin§ (pg/mL) 500.0 (59.5 – 700.0) 932.4 (701.4 – 1287.5) 2078.9 (1289.5 – 12361.1) < 0.0001
Models
T2D Reference OR (95% CI) OR (95% CI)
Model 1 1 2.82 (1.92 – 4.14) 10.94 (7.29 – 16.42) < 0.0001
Model 2 1 2.66 (1.80 – 3.92) 10.09 (6.68 – 15.24) < 0.0001
Model 3 1 1.52 (0.82 – 2.79) 7.37 (3.87 – 14.04) < 0.0001
Model 4 1 1.46 (0.78 – 2.73) 6.15 (3.15 – 12.01) < 0.0001
Table 3. Multiple logistic regression models for diabetes in relation to betatrophin. Model 1 adjusted for age, 
gender, and ethnicity; Model 2 adjusted for BMI, waist/hip ratio + Model 1; Model 3 adjusted for HbA1c, 
HOMA-IR, and HOMA-β + Model 2. Model 4 adjusted for total cholesterol, triglyceride, LDL, HDL, 
systolic, diastolic blood pressure + Model 3. Tertile values of betatrophin are expressed as T1 (< 700.0), T2 
(700.0 – 1287.5), and T3 (> 1287.5). §Betatrophin presented as Median (range).
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in T2D and T1D19–21,26. However, a recent report found that betatrophin level was reduced in T2D29. Fu 
et al., suggested that the discrepancies were caused by different betatrophin species that were measured 
using different ELISA kits28. Even though this represents a good possibility, differences in sample size 
and ethnic groups across studies may also contribute to different findings19–21,29.
Age was another factor that positively correlated with betatrophin levels in both T2D and non-diabetic 
subjects. A similar trend was observed in other studies21,26,27. Espes et al. showed that betatrophin levels 
were higher in older non-T1D control individuals, while T1D patients did not show a similar trend26. In 
contrast, T2D patients in our population showed an age dependent increase in their betatrophin levels. 
The difference between the two types of diabetes is interesting and supports a possible functional impor-
tance of betatrophin in T2D, where it could be playing a role in compensating for the increased insu-
lin demand. This is in agreement with previous reports which highlighted the attenuated induction of 
Figure 2. Betatrophin level distribution according to insulin resistance and FBG. A: Age-, gender-, and 
ethnicity-adjusted least square means of concentrations of betatrophin according to HOMA-IR. Tertile 
values of HOMA-IR are expressed as T1 (≤ 1.6), T2 (> 1.6 & ≤ 3.1), and T3 (> 3.1). B: Age-, gender-, and 
ethnicity-adjusted least square means of concentrations of betatrophin according to FBG and HOMA-IR. 
T2D: FBG ≥ 7 mmol/l, under treatment, or self-reported of previously diagnosed T2D; IFG: fasting blood 
glucose values ≥ 5.6 and < 7 mmol/L. LSMean: Least Square Mean.
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β -cell proliferation in older mice when compared to young mice30 and in adult human β -cells compared 
to embryonic and neonatal β -cells31,32. However, the lack of association between betatrophin level and 
FBG and HOMA-IR in diabetic subjects raises serious concern about the functional use of betatrophin 
especially in light of recent reports showing that human β -cells were not responsive to the increase in 
betatrophin level33. In addition, the recent critical paper by Gusarova et al. showed that β -cell expansion 
under insulin resistance conditions was not affected by the deletion of both copies of betatrophin17. 
Nonetheless, the increased level of betatrophin in T2D subjects is interesting and further raises the 
question about the actual function of betatrophin especially after the recent reports confirming that beta-
trophin does not affect the beta cell expansion in mice17,18 and humans33. More studies will be required 
to answer these questions and better establish the cellular role of betatrophin in T2D.
In addition to using a large sample set, our study focused on a high risk group where recent epide-
miological data from Arabian Gulf countries warned of the high prevalence of obesity and T2D34–37. 
According to International Diabetes Federation (IDF) Bahrain, Kuwait, Oman, Saudi Arabia, and United 
Arab Emirates ranked amongst the highest countries in the world with T2D35,37. Asians on the other 
hand have a higher risk for hypertension, T2D, cholesterol profiles and cardiovascular disease38. One of 
the main limitations of the current study is the cross sectional nature that cannot establish causality. In 
conclusion, we showed that betatrophin level was increased in T2D subjects albeit it did not correlate 
with FBG or insulin resistance in these patients. On the other hand, betatrophin levels were significantly 
correlated with FBG and insulin resistance in non-diabetic subjects. The increased betatrophin levels 
with age in both T2D and non-diabetic subjects can potentially represent a possible compensatory cel-
lular mechanism in older subjects. More studies will be required to determine any causal relationship 
between betatrophin and T2D.
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